Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately respiratory failure. Often known as Lou Gehrig’s disease, ALS impacts voluntary muscle control, drastically reducing a patient’s ability to move, speak, or breathe. Despite extensive research, the exact cause remains elusive, making early detection and advanced therapeutic development a global priority.

The Amyotrophic Lateral Sclerosis (ALS) session highlights advancements in understanding ALS pathophysiology, genetic risk factors, and neuroprotective treatments aimed at extending survival and improving quality of life. This scientific session examines molecular pathways contributing to neuron degeneration and explores clinical innovations improving patient care outcomes.

As discussed at ALS Conference forums worldwide, researchers are applying molecular genetics, stem cell therapy, and biomarker-based diagnosis to unravel new possibilities for treatment. AI-driven neuroimaging and computational modeling are accelerating progress in identifying predictive markers and monitoring disease progression.

This session invites neurologists, neurobiologists, geneticists, and rehabilitation experts to share insights on ongoing trials, emerging drug pipelines, and multidisciplinary care models supporting patients and caregivers. Participants will learn about personalized medicine, neuroengineering approaches, and community programs shaping the future of ALS management.

Breakthroughs in Motor Neuron Disease research continue to bring hope for restoring motor function and discovering effective disease-modifying therapies.